Detalhe da pesquisa
1.
Working with benchmark datasets in the Cuby framework.
J Chem Phys
; 160(20)2024 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38775240
2.
Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
J Antimicrob Chemother
; 77(4): 1166-1177, 2022 03 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35022730
3.
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
Crit Care
; 25(1): 290, 2021 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34380538
4.
Loss of Consciousness and Prolonged Convulsions Due to Amanita Pantherina Intoxication.
Neuro Endocrinol Lett
; 44(8): 500-505, 2023 Dec 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38131173
5.
Non-Covalent Interactions Atlas Benchmark Data Sets 3: Repulsive Contacts.
J Chem Theory Comput
; 17(3): 1548-1561, 2021 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33620192
6.
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
Lancet Infect Dis
; 19(12): 1299-1311, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31563344